Comparative Pharmacology
Head-to-head clinical analysis: CYMBALTA versus PRISTIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYMBALTA versus PRISTIQ.
CYMBALTA vs PRISTIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin and norepinephrine reuptake inhibitor (SNRI); increases extracellular levels of serotonin and norepinephrine by inhibiting their reuptake into presynaptic neurons.
Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI). It binds to the serotonin transporter (SERT) and norepinephrine transporter (NET), inhibiting reuptake of serotonin and norepinephrine, thereby increasing their synaptic concentrations.
60 mg orally once daily, without regard to meals; some patients may benefit from a starting dose of 30 mg once daily for 1 week before increasing to 60 mg once daily.
50 mg orally once daily, with or without food; may increase by 50 mg every 7 days to a maximum of 100 mg once daily; maximum dose is 100 mg/day (some studies up to 400 mg/day but not recommended).
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 8–17 hours); supports once-daily dosing with consistent drug levels.
Desvenlafaxine: ~11 hours (range 8-15 h); supports once-daily dosing
Renal: approximately 70% as metabolites (duloxetine glucuronide conjugates and sulfate conjugates), 20% as unchanged drug in urine; fecal: approximately 20% as metabolites; biliary: minor contribution.
Renal: 87% (45% desvenlafaxine unchanged, 42% as metabolites); biliary/fecal: minimal (<1%)
Category C
Category C
SNRI Antidepressant
SNRI Antidepressant